肝胆胰外科杂志2023，Vol.35Issue(12)：731-735,5.DOI:10.11952/j.issn.1007-1954.2023.12.007
TACE联合卡瑞利珠单抗及阿帕替尼治疗晚期肝细胞癌的临床研究
The clinical effect of TACE combined with Camrelizumab and Apatinib in the treatment of advanced hepatocellular carcinoma
摘要
Abstract
Objective To analyze the clinical efficacy and safety of TACE combined with Camrelizumab and Apatinib in the treatment of advanced hepatocellular carcinoma(HCC).Methods Between Mar.2019 and Mar.2022,37 patients with advanced HCC were enrolled in the study.Patients received transcatheter arterial chemoembolization(TACE)combined with immunotherapy(Camrelizumab)and targeted therapy(Apatinib).The patient's blood indicators,tumor stage,and imaging features before treatment were recorded;the patient's blood indicators and imaging findings after treatment,as well as any adverse reactions occurred during the treatment process were followed-up.The clinical efficacy was analyzed by objective response rate(ORR),disease control rate(DCR),progression free survival time(PFS),and overall survival time(OS),and the corresponding survival curves were drawed by Kaplan-Meier analysis;the safety of combined therapy was evaluated by adverse reactions.Results Among 37 advanced HCC patients,5 cases were lost during follow-up,and 9 cases died.The ORR and DCR were 48.65%(18/37)and 75.68%(28/37),respectively;with 9.5 months for PFS and 12.2 months for OS.Camrelizumab and Apatinib treatment-related adverse events occurred in 24 cases(64.86%),and no treatment-related deaths occurred.Conclusion This preliminary study shows that,for treatment of advanced HCC,the combination of TACE,immunotherapy(Camrelizumab)and targeted therapy(Apatinib)can improve patient's survival time,achieve high tumor control rates and low incidence rate of adverse drug reactions.关键词
肝细胞癌/经导管肝动脉化疗栓塞/免疫治疗/靶向治疗/卡瑞利珠单抗/阿帕替尼Key words
hepatocellular carcinoma/transcatheter arterial chemoembolization/Apatini/Camrelizumab分类
医药卫生引用本文复制引用
石银生,方剑,姜继华,姜仁鸦..TACE联合卡瑞利珠单抗及阿帕替尼治疗晚期肝细胞癌的临床研究[J].肝胆胰外科杂志,2023,35(12):731-735,5.基金项目
浙江省医药卫生科技计划项目(2021KY1191). （2021KY1191）
